BioVersys and collaborators report preclinical data for alpibectir–ethionamide (AlpE) in Nature Communications, showing activity against drug-resistant tuberculosis and supporting ongoing Phase 2 trials in pulmonary TB and TB meningitis.
Written by: Mennatullah Mansour, PharmD
Reviewed By: Pharmacally Editorial Team
BioVersys and its partners announced the publication of preclinical development data for alpibectir in combination with ethionamide (AlpE) in Nature Communications. The data describe the mechanism of action and activity of AlpE against drug-resistant Mycobacterium tuberculosis. The combination is being developed for the treatment of pulmonary tuberculosis and tuberculosis meningitis in collaboration with GSK, Institut Pasteur de Lille, and the University of Lille.
Regulatory milestones include Orphan Drug Designation granted by the U.S. Food and Drug Administration in 2023, providing seven-year exclusivity, and Orphan Designation granted by the European Medicines Agency in 2025, providing ten-year exclusivity.
Clinical development program
The clinical development program includes a Phase 2b pulmonary tuberculosis trial (NCT05807399) sponsored by GSK under the IMI2 UNITE4TB program, evaluating AlpE in combination with first-line TB therapies, with recruitment expected to be completed by the end of 2027. In parallel, a Phase 2 trial in tuberculosis meningitis (NCT07350174), sponsored by BioVersys, has recently been initiated.
Primary endpoints for these studies include reduction in bacterial load and time to sputum culture conversion in pulmonary tuberculosis, as well as clinical response and survival in meningeal tuberculosis. Secondary endpoints include safety and tolerability, pharmacokinetics, pharmacodynamics, and activity against drug-resistant strains.
Supporting clinical data and safety
Alpibectir has completed Phase 1 studies and two Phase 2a pulmonary tuberculosis trials. Reported findings indicate that the compound is generally safe and well tolerated, with clinical proof-of-concept established for the AlpE combination in pulmonary tuberculosis. Across Phase 1 and Phase 2a studies, no quantitative safety event rates were disclosed in the available data.
Preclinical findings
Preclinical data include in vitro studies demonstrating activity against multiple M. tuberculosis clinical strains, including drug-resistant isolates, as well as activity in intracellular infection models. In vivo studies showed reductions in bacterial load and improvements in survival outcomes, supporting translation from in vitro findings to in vivo proof of concept. Mechanistic analyses indicate that alpibectir enhances the bioactivation of ethionamide, restores susceptibility in resistant strains, and demonstrates bactericidal activity when used in combination as AlpE.
Leadership commentary
Dr. Michel Pieren of BioVersys stated that the data provide a scientific foundation for understanding the potential positioning of AlpE in future tuberculosis treatment regimens and support further clinical development.
Dr. Alain Baulard of the Institut Pasteur de Lille noted that alpibectir reprograms the transcriptional landscape of M. tuberculosis, increasing the activity of ethionamide and informing rational combination strategies.
Dr. David Barros-Aguirre of GSK added that publication of the preclinical data supports continued progress of the treatment in clinical development and highlights the value of collaborative research.
Next steps
BioVersys plans to complete enrollment in the Phase 2b pulmonary tuberculosis trial by 2027 while continuing the ongoing Phase 2 study in tuberculosis meningitis. The company is also evaluating AlpE in combination regimens with standard therapies, with further development decisions, including potential progression to Phase 3, expected to be guided by Phase 2 outcomes.
References
Data published in Nature Communications highlights unique Mechanism of Action of Alpibectir in combination with Ethionamide (AlpE) | BioVersys, 13 April 2026.
Edoo, Z., Grosse, C., Maitre, T. et al. Alpibectir–Ethionamide combination (AlpE) for the treatment of tuberculosis. Nat Commun (2026). https://doi.org/10.1038/s41467-026-71460-6
Michel Pieren et al, Revival of Ethionamide by Alpibectir, Published February 18, 2026 N Engl J Med 2026;394:818-819, Revival of Ethionamide by Alpibectir | New England Journal of Medicine
About the Writer
Mennatullah Mansour is pursuing a PharmD and is based in Alexandria, Egypt. She is driven by a strong passion for continuous learning and professional development, with a focus on pharmaceutical care, patient health, and medication safety. Her interests include prescription processing, patient counseling, and interpreting clinical information. She brings a detail-oriented approach and a strong ability to translate medical knowledge into clear, accurate, and reliable content for healthcare audiences.